Colleen Cutcliffe
Colleen Cutcliffe is a molecular biologist and a co-founder of Pendulum Therapeutics. She discusses gut bacteria, including Akkermansia, and how her company studies and develops probiotic formulations.
Statements
21 statements
Colleen Cutcliffe explains how different microbes can turn dietary fibers into compounds used to produce butyrate.
Colleen Cutcliffe describes how more than one type of gut bacterium can participate in converting fiber into butyrate.
Colleen Cutcliffe distinguishes the species Akkermansia muciniphila from a specific strain in response to a question from Peter Attia.
Colleen Cutcliffe uses cranberry juice as an analogy in her discussion and says she is unsure how far the comparison applies.
Colleen Cutcliffe discusses the difficulty of keeping oxygen out when manufacturing probiotic strains that are sensitive to it.
Colleen Cutcliffe distinguishes probiotic organisms from the substrates they use. She gives inulin and other dietary fibers as examples of prebiotics that can feed gut microbes.
Colleen Cutcliffe explains what colony-forming units count on a probiotic label. The method counts microbes that can form colonies under the test conditions. She mentions flow cytometry as another way to examine the contents of a capsule.
Colleen Cutcliffe says she does not know how common the Lactobacillus example is and shifts to how probiotics are manufactured.
Colleen Cutcliffe describes what she would do if taking antibiotics and why she would emphasize dietary fiber afterward.
Colleen Cutcliffe discusses fruit as a source of fiber and polyphenols in a conversation about diet after antibiotics. She describes these compounds as substrates that can influence the gut microbiome. The passage concerns food choices and does not test a prebiotic supplement.
Colleen Cutcliffe describes which Akkermansia species she says accounts for much of the research and distinguishes it from other members of the genus.
Colleen Cutcliffe describes the anaerobic production methods used in probiotic manufacturing.
Colleen Cutcliffe discusses how competing probiotic products are described on their labels.
Colleen Cutcliffe proposes that a metabolite such as butyrate can help stimulate GLP-1 release.
Colleen Cutcliffe names two bacterial strains and describes an interaction she expects between them.
Colleen Cutcliffe explains how one bacterium can make propionate and another can use it to produce butyrate.
Colleen Cutcliffe describes how butyrate and propionate may signal through receptors in the gut and stimulate the release of GLP-1.
Colleen Cutcliffe explains why her team tested a blend of five bacterial strains, including Akkermansia muciniphila. The team wanted other strains to convert propionate to butyrate. The trial tested the complete blend with inulin, so it cannot isolate the effect of Akkermansia.
Colleen Cutcliffe explains why a probiotic formula can include more than one strain capable of turning dietary fiber into propionate or acetate.
Colleen Cutcliffe explains why she thinks butyrate made by gut microbes may act differently from butyrate taken by mouth.
